EyePoint climbs on Q4 revenue beat

EyePoint

07/03/2024 13:06

** Shares of EyePoint Pharmaceuticals  EYPT.O  rise ~4.9% to
$27 premarket
    ** Co's Q4 revenue of $14 million beats analysts' average
expectation of $8.9 mln - LSEG data
    ** Co expects its cash, cash equivalents and investments of
$331 mln to fund the late-stage trials of its eye disorder
treatment in 2026
    ** Up to last close, stock up more than eight-fold in the
last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))